FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1566145495> ?p ?o ?g. }

• W1566145495 endingPage "04" @default.
• W1566145495 startingPage "P6" @default.
• W1566145495 abstract "Abstract Background : CDK4-associated kinase activity is required to maintain breast tumorigenesis. Virtually all ER-positive cell lines harbour loss of p16ink4a. Low expression of CDK inhibitors p21 and p27 and high expression level of cyclin E and D1 have all been associated with resistance to anti-estrogen therapy. In preclinical models, Rb deficiency is associated with resistance to antiestrogen therapy. Palbociclib (PD 0332991, Pfizer Inc.) is an oral, potent, highly selective reversible inhibitor of CDK4/6 that prevents cellular DNA synthesis by prohibiting progression from G1 into the S phase. Palbociclib in combination with letrozole has shown promising activity in metastatic setting. Methods : In an open-label, multi-center, single arm pilot study efficacy and safety of neo-adjuvant palbociclib 100 mg QD for 3 weeks plus letrozole 2.5 mg QD in 4 week cycles for 4 months was studied. Postmenopausal patients of mostly Chinese ancestry, with histologically confirmed ER+, HER2- invasive breast cancer and tumor greater than 2 cm were registered. Patients with T3N1, T4 or any N2, N3 were excluded. Aim : The primary endpoint is Objective Response Rate (ORR). The secondary end-point include Pathologic Response Rate (PRR), Disease-Free Survival (DFS), safety. Exploratory analysis of gene and protein expression in tumors and serial whole blood is planned. Results : As of June 2014, 11 patients were recruited. 9 patients completed treatment and 2 are still on study. Of the 9 patients that completed study at time of this abstract, 1 patient had a complete pathological response (pCR) and 7 had a partial response (ORR of 89%). Baseline Ki67 levels were low (median 18%), consistent with luminal type A disease. On average, patients underwent surgery 24 days after completion of the study. Ki67 was measured at baseline, cycle 1 day 15, and at the time of surgery. Median Ki67 at time of surgery was 10%. There were no significant changes in Ki67 that could be related to treatment outcome based on this preliminary data analysis in surgical samples only. In the first 8 patients, whom all started at a dose of 125mg palbociclib, 4 patients developed grade 3/4 neutropenia in the absence of fever. Neutropenia was well manageable with G-CSF and/or dose modification. Protocol amendment allowed starting dose of 100 mg with dose titration to 125mg after the first cycle. 3 patients started at 100mg and grade 4 neutropenia without fever occurred in 1 subject. Another common side effect was low grade mucositis (n=5). Conclusion : Based on these initial results, the addition of palbociclib to neo-adjuvant letrozole appears to be safe and effective. Historically, ORR in this patient population with letrozole alone is below 55%. The addition of palbociclib increased the preliminary ORR to 89%. One patient had a pCR, uncommon for patients on neo-adjuvant endocrine therapy. Complete safety and efficacy data will be included for at least 11 patients, including initial biomarker results. The study continues enrolment up to 45 patients. Citation Format: Louis WC Chow, Chi-Kei Lam, Wings TY Loo. OOTR-N007: A phase II neoadjuvant study of letrozole plus palbociclib in postmenopausal patients with ER positive, HER2 negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-11-04." @default.
• W1566145495 created "2016-06-24" @default.
• W1566145495 creator A5040716742 @default.
• W1566145495 creator A5070238193 @default.
• W1566145495 creator A5087060680 @default.
• W1566145495 date "2015-05-01" @default.
• W1566145495 modified "2023-09-27" @default.
• W1566145495 title "Abstract P6-11-04: OOTR-N007: A phase II neoadjuvant study of letrozole plus palbociclib in postmenopausal patients with ER positive, HER2 negative breast cancer" @default.
• W1566145495 doi "https://doi.org/10.1158/1538-7445.sabcs14-p6-11-04" @default.
• W1566145495 hasPublicationYear "2015" @default.
• W1566145495 type Work @default.
• W1566145495 sameAs 1566145495 @default.
• W1566145495 citedByCount "4" @default.
• W1566145495 countsByYear W15661454952016 @default.
• W1566145495 countsByYear W15661454952017 @default.
• W1566145495 countsByYear W15661454952018 @default.
• W1566145495 crossrefType "journal-article" @default.
• W1566145495 hasAuthorship W1566145495A5040716742 @default.
• W1566145495 hasAuthorship W1566145495A5070238193 @default.
• W1566145495 hasAuthorship W1566145495A5087060680 @default.
• W1566145495 hasConcept C121608353 @default.
• W1566145495 hasConcept C126322002 @default.
• W1566145495 hasConcept C143998085 @default.
• W1566145495 hasConcept C203092338 @default.
• W1566145495 hasConcept C2775930923 @default.
• W1566145495 hasConcept C2777176818 @default.
• W1566145495 hasConcept C2778812593 @default.
• W1566145495 hasConcept C2779744173 @default.
• W1566145495 hasConcept C2780482068 @default.
• W1566145495 hasConcept C530470458 @default.
• W1566145495 hasConcept C535046627 @default.
• W1566145495 hasConcept C71924100 @default.
• W1566145495 hasConceptScore W1566145495C121608353 @default.
• W1566145495 hasConceptScore W1566145495C126322002 @default.
• W1566145495 hasConceptScore W1566145495C143998085 @default.
• W1566145495 hasConceptScore W1566145495C203092338 @default.
• W1566145495 hasConceptScore W1566145495C2775930923 @default.
• W1566145495 hasConceptScore W1566145495C2777176818 @default.
• W1566145495 hasConceptScore W1566145495C2778812593 @default.
• W1566145495 hasConceptScore W1566145495C2779744173 @default.
• W1566145495 hasConceptScore W1566145495C2780482068 @default.
• W1566145495 hasConceptScore W1566145495C530470458 @default.
• W1566145495 hasConceptScore W1566145495C535046627 @default.
• W1566145495 hasConceptScore W1566145495C71924100 @default.
• W1566145495 hasIssue "9_Supplement" @default.
• W1566145495 hasLocation W15661454951 @default.
• W1566145495 hasOpenAccess W1566145495 @default.
• W1566145495 hasPrimaryLocation W15661454951 @default.
• W1566145495 hasRelatedWork W2007182497 @default.
• W1566145495 hasRelatedWork W2762467781 @default.
• W1566145495 hasRelatedWork W2767256081 @default.
• W1566145495 hasRelatedWork W2931385471 @default.
• W1566145495 hasRelatedWork W2972634993 @default.
• W1566145495 hasRelatedWork W2977498541 @default.
• W1566145495 hasRelatedWork W3089092305 @default.
• W1566145495 hasRelatedWork W3136162983 @default.
• W1566145495 hasRelatedWork W3165971608 @default.
• W1566145495 hasRelatedWork W4206663964 @default.
• W1566145495 hasVolume "75" @default.
• W1566145495 isParatext "false" @default.
• W1566145495 isRetracted "false" @default.
• W1566145495 magId "1566145495" @default.
• W1566145495 workType "article" @default.